Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2Sarcoma 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2

Interventions

Cisplatin 70Paclitaxel 68pembrolizumab 65Carboplatin 61Irinotecan 59Injections 53Gemcitabine 53Docetaxel 49Fluorouracil 35Cyclophosphamide 35Pemetrexed 34Oxaliplatin 31Capecitabine 30Bevacizumab 29Leucovorin 27atezolizumab 23Nivolumab 23tislelizumab 19Etoposide 18Cetuximab 17durvalumab 16Temozolomide 16Bortezomib 16alvocidib 15Topotecan 15olaparib 14Sorafenib 14Rifampin 14Itraconazole 14Erlotinib Hydrochloride 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × trioctyl phosphine oxide × Other solid neoplasm × Clear all
NCT00541359 2017-08-09

Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

City of Hope Medical Center

Phase 1 Completed
54 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00068484 2013-02-01

A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡